(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.23%) $79.17
(-0.59%) $2.17
(-0.24%) $2 316.70
(-0.06%) $27.59
(0.07%) $985.30
(0.08%) $0.930
(0.11%) $10.91
(0.10%) $0.800
(0.33%) $91.75
Live Chart Being Loaded With Signals
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases...
Stats | |
---|---|
今日成交量 | 69 814.00 |
平均成交量 | 60 708.00 |
市值 | 2.88M |
EPS | €0 ( 2024-04-14 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.0700 |
ATR14 | €0.00600 (0.73%) |
音量 相关性
Biophytis SA 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Biophytis SA 相关性 - 货币/商品
Biophytis SA 财务报表
Annual | 2023 |
营收: | €0 |
毛利润: | €-803 000 (0.00 %) |
EPS: | €-12.54 |
FY | 2023 |
营收: | €0 |
毛利润: | €-803 000 (0.00 %) |
EPS: | €-12.54 |
FY | 2022 |
营收: | €0 |
毛利润: | €-484 000 (0.00 %) |
EPS: | €-0.130 |
FY | 2021 |
营收: | €0.00 |
毛利润: | €0.00 (0.00 %) |
EPS: | €-0.260 |
Financial Reports:
No articles found.
Biophytis SA
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。